Wilson AP, Shankar S, Felmingham D, Treasure T, Gruneberg RN. Serum and tissue levels of teicoplanin during cardiac surgery: the effect of a high dose regimen. J Antimicrob Chemother. 1989;23(4):613–7.

Article  CAS  PubMed  Google Scholar 

Aulin LBS, De Paepe P, Dhont E, de Jaeger A, Vande Walle J, Vandenberghe W, et al. Population pharmacokinetics of unbound and total teicoplanin in critically ill pediatric patients. Clin Pharmacokinet. 2021;60(3):353–63.

Article  CAS  PubMed  Google Scholar 

Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev. 2010;16(6):Cd007022.

Google Scholar 

European Medicines Agency. Summary of the product characteristics; 2013.

Bernareggi A, Danese A, Cometti A, Buniva G, Rowland M. Pharmacokinetics of individual components of teicoplanin in man. J Pharmacokinet Biopharm. 1990;18(6):525–43.

Article  CAS  PubMed  Google Scholar 

Rowland M. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 1990;18(3):184–209.

Article  CAS  PubMed  Google Scholar 

The European Committee on Antimicrobial Susceptibility Testing. Teicoplanin rationale for the EUCAST clinical breakpoints, version 2.1 2010.

Watanabe E, Matsumoto K, Ikawa K, Yokoyama Y, Shigemi A, Enoki Y, et al. Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model. J Glob Antimicrob Resist. 2021;24:83–7.

Article  CAS  PubMed  Google Scholar 

Ramos-Martín V, Johnson A, McEntee L, Farrington N, Padmore K, Cojutti P, et al. Pharmacodynamics of teicoplanin against MRSA. J Antimicrob Chemother. 2017;72(12):3382–9.

Article  PubMed  Google Scholar 

Kanazawa N, Matsumoto K, Ikawa K, Fukamizu T, Shigemi A, Yaji K, et al. An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication. J Infect Chemother. 2011;17(2):297–300.

Article  PubMed  Google Scholar 

Hagihara M, Umemura T, Kimura M, Mori T, Hasegawa T, Mikamo H. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus. J Infect Chemother. 2012;18(1):10–6.

Article  CAS  PubMed  Google Scholar 

Matsumoto K, Watanabe E, Kanazawa N, Fukamizu T, Shigemi A, Yokoyama Y, et al. Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections. Clin Pharmacol. 2016;2016(8):15–8.

Google Scholar 

Wilson APR. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000;39(3):167–83.

Article  CAS  PubMed  Google Scholar 

Harding I, MacGowan AP, White LO, Darley ES, Reed V. Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother. 2000;45(6):835–41.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

Article  PubMed  PubMed Central  Google Scholar 

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.

Article  PubMed  PubMed Central  Google Scholar 

Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783–95.

Article  PubMed  Google Scholar 

Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25–36.

Article  CAS  PubMed  Google Scholar 

Buniva G, Del Favero A, Bernareggi A, Patoia L, Palumbo R. Pharmacokinetics of 14C-teicoplanin in healthy volunteers. J Antimicrob Chemother. 1988;21(Suppl A):23–8.

Article  PubMed  Google Scholar 

Lagast H, Dodion P, Klastersky J. Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin. J Antimicrob Chemother. 1986;18(4):513–20.

Article  CAS  PubMed  Google Scholar 

Ripa S, Ferrante L, Mignini F, Falcioni E. Pharmacokinetics of teicoplanin. Chemotherapy. 1988;34(3):178–84.

Article  CAS  PubMed  Google Scholar 

Traina GL, Gentile MG, Fellin G, Rosina R, Cavenaghi L, Buniva G, et al. Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol. 1986;31(4):501–4.

Article  CAS  PubMed  Google Scholar 

Wise R, Donovan IA, McNulty CA, Waldron R, Andrews JM. Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration. J Hosp Infect. 1986;7(Suppl A):47–55.

Article  PubMed  Google Scholar 

Kontou A, Sarafidis K, Begou O, Gika HG, Tsiligiannis A, Ogungbenro K, et al. Population pharmacokinetics of teicoplanin in preterm and term neonates: is it time for a new dosing regimen? Antimicrob Agents Chemother. 2020;64(4):e01971–19.

Ramos-Martín V, Neely M, McGowan P, Siner S, Padmore K, Peak M, et al. Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. England; 2016.

Yamada T, Fukuda T, Emoto C, Mizuno T, Egashira N, Masuda S. Teicoplanin optimal dosing regimen in neonates and children developed by leveraging real-world clinical information. Clin Pharmacol Ther. 2020;107:S103-S.

Google Scholar 

Lukas J, Karikas G, Gazouli M, Kalabalikis P, Hatzis T, Macheras P. Pharmacokinetics of teicoplanin in an ICU population of children and infants. United States; 2004.

Gao L, Xu H, Ye Q, Li S, Wang J, Mei Y, et al. population pharmacokinetics and dosage optimization of teicoplanin in children with different renal functions. Front Pharmacol. 2020;2020(11):552.

Article  Google Scholar 

Zhang T, Sun D, Shu Z, Duan Z, Liu Y, Du Q, et al. Population pharmacokinetics and model-based dosing optimization of teicoplanin in pediatric patients. Front Pharmacol. 2020;2020(11): 594562.

Article  Google Scholar 

Fu WQ, Tian TT, Zhang MX, Song HT, Zhang LL. Population pharmacokinetics and dosing optimization of unbound teicoplanin in Chinese adult patients. Front Pharmacol. 2022;2022(13):1045895.

Article  Google Scholar 

Enokiya T, Muraki Y, Iwamoto T, Okuda M. Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: impact of albumin glycosylation on the binding of teicoplanin to albumin. Int J Antimicrob Agents. 2015;46(2):164–8.

Article  CAS  PubMed  Google Scholar 

Steer JA, Papini RP, Wilson AP, Dhillon S, Hichens MF, McGrouther DA, et al. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother. 1996;37(3):545–53.

Article  CAS  PubMed  Google Scholar 

Rybak MJ, Lerner SA, Levine DP, Albrecht LM, McNeil PL, Thompson GA, et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Infectious Diseases Division, Department of Medicine, Harper Hospital, Detroit, MI 48201, United States; 1991.

Nakamura T, Igarashi T, Yano R, Tsukamoto H, Hashimoto Y, Masada M. Population pharmacokinetics of teicoplanin in patients and simulation of trough concentrations after various initial loading doses. J Appl Ther Res. 2008;6(4):32–40.

CAS  Google Scholar 

Lesne-Hulin A, Bourget P, Le Bever H, Ainaud P, Carsin H. Clinical pharmacokinetics of amikacin-teicoplanin in infected severely burned patients: a pilot study. Medecine et Maladies Infectieuses. 1997;27(3):306–13.

Article  Google Scholar 

Lamont E, Seaton RA, Macpherson M, Semple L, Bell E, Thomson AH. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrob Chemother. 2009;64(1):181–7.

Article  CAS  PubMed  Google Scholar 

Kasai H, Tsuji Y, Hiraki Y, Tsuruyama M, To H, Yamamoto Y. Population pharmacokinetics of teicoplanin in hospitalized elderly patients using cystatin C as an indicator of renal function. J Infect Chemother. 2018;24(4):284–91.

Article  CAS  PubMed  Google Scholar 

Ma P, Shang S, Liu R, Dong Y, Wu J, Gu W, et al. Prediction of teicoplanin plasma concentration in critically ill patients: a combination of machine learning and population pharmacokinetics. J Antimicrob Chemother. 2024;79(11):2815–27.

Article  CAS  PubMed  Google Scholar 

Roberts JA, Stove V, De Waele JJ, Sipinkoski B, McWhinney B, Ungerer JP, et al. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI study. Int J Antimicrob Agents. 2014;43(5):423–30.

Article  CAS  PubMed